Skip to main content
. 2013 Nov;57(11):5559–5564. doi: 10.1128/AAC.00500-13

Fig 4.

Fig 4

Efficacy of lysozyme treatments (n = 5 mice per group). (A) Reduction in the numbers of P. aeruginosa CFU with escalating doses of charge-engineered lysozyme 2-3-7 (ANOVA, P = 0.005); (B) numbers of lung P. aeruginosa CFU following treatment with PBS, 100 μg of wild-type hLYS, or 100 μg of variant 2-3-7 (ANOVA, P = 0.0002). The means ± SEMs are indicated. *, P < 0.05 compared with the PBS control group; **, P < 0.01 compared with the PBS control group; ***, P < 0.001 compared with the PBS control group.